Live Wire Reporter

Type 1 Diabetes Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Type 1 Diabetes Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 13
21:49 2023
Type 1 Diabetes Emerging and Marketed Drugs Assessment, (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 100+ pipeline drugs in the Type 1 Diabetes therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Type 1 Diabetes therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Diabetes, increased healthcare spending worldwide, and the expected launch of emerging drugs in the market. Currently, key players such as Provention Bio, Oramed, Eli Lilly, Novo Nordisk, REMD Biotherapeutics, and several others are actively working in the Type 1 Diabetes therapeutics market.

Type 1 Diabetes Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Type 1 Diabetes Market. 

The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Type 1 Diabetes Pipeline Analysis

Type 1 Diabetes Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Type 1 Diabetes and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Type 1 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous 

Molecule Type

The emerging pipeline products have been categorized under various Molecule types in the report, such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

  • CD40 antigen inhibitor

  • Interleukin 8A and 8B receptor antagonist

  • Ornithine decarboxylase stimulant

  • Glucagon receptor agonist

  • Cytotoxic T lymphocyte stimulant

  • Interleukin-2 replacement

  • Undefined mechanism

Learn How the Ongoing Clinical & Commercial Activities will Affect the Type 1 Diabetes Therapeutic Segment @

Type 1 Diabetes Therapeutics Landscape

There are approx. 80+ key companies developing therapies for Type 1 Diabetes. Currently, Provention Bio is leading the therapeutics market with its Type 1 Diabetes drug candidates in the most advanced stage of clinical development.

Leading Companies in the Type 1 Diabetes Therapeutics Market Include:

Adocia, Amytrx, Anelixis Therapeutics, Arecor, AstraZeneca, Avotres, Bioprojet, Diamyd Medical, Dompe Pharmaceutical, Eli Lilly, Gan&Lee Pharmaceuticals, Histogen, ImCyse, Kamada, Landos Biopharma, Novartis, Novo Nordisk, Oramed, Panbela Therapeutics, Precigen ActoBiotics, Prevention Bio, REMD Biotherapeutics, TikoMed, Tolerion, Vertex Pharmaceuticals, Zealand Pharma, and many others.

Type 1 Diabetes Emerging and Marketed Drugs Analyzed in the Report Include:

  • AG019: Precigen ActoBiotics

  • AMTX 100: Amytrx

  • Basal insulin-Fc: Eli Lilly

  • Emricasan: Histogen

  • IMCY-0098: ImCyse

  • Insulin icodec: Novo Nordisk

  • Iscalimab: Novartis

  • Ladarixin: Dompe Pharmaceutical

  • LY3209590: Eli Lilly and Company Therapeutics

  • MHS552: Novartis

  • NNC0471-0119: Novo Nordisk

  • ORMD-0801: Oramed

  • Teplizumab: Prevention Bio

  • Volagidemab: REMD Biotherapeutics

  • VX-880: Vertex Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Type 1 Diabetes Current Treatment Patterns

4. Type 1 Diabetes – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Type 1 Diabetes Late Stage Products (Phase-III)

7. Type 1 Diabetes Mid-Stage Products (Phase-II)

8. Type 1 Diabetes Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Type 1 Diabetes Discontinued Products

13. Type 1 Diabetes Product Profiles

14. Key Companies in the Type 1 Diabetes Market

15. Key Products in the Type 1 Diabetes Therapeutics Segment

16. Dormant and Discontinued Products

17. Type 1 Diabetes Unmet Needs

18. Type 1 Diabetes Future Perspectives

19. Type 1 Diabetes Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About Author